
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Q I am inquiring about a very active, intense 12-month-old boy who sleeps in his parents' bedroom on a mattress on the floor.






